Eye Infections Treatment Market- Sales Analysis Report 2030

Eye Infections Treatment Market Outlook (2022-2030)

[256 Pages Report] Worldwide revenue from the global Eye Infections Treatment Market is estimated at US$ 7.3 Billion for 2022, and the market is projected to progress at a CAGR of 3.8% from 2022 to 2030. Demand for eye infections treatment is anticipated to reach a worth of US$ 9.9 Billion by the end of 2030.

Attributes	Details
Eye Infections Treatment Market Size (2022)	US$ 7.3 Billion
Predicted Revenue (2030)	US$ 9.9 Billion
Forecasted Growth Rate (2022 to 2030)	3.8% CAGR
Dominant Dosage Form	Eye Drops - 60.2%

Eye infections treatment products account for 17.2% share of the global antibiotic market at present. OTC eye infection drops are expected to have a bright outlook over the decade.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars	Details
H1, 2021	3.79%
H1, 2022 Projected	3.84%
H1, 2022 Outlook	3.74%
BPS Change - H1, 2022 (O) - H1, 2022 (P)	(-) 10 ↓
BPS Change - H1, 2022 (O) - H1, 2021	(-) 05 ↓

As per the FMI analysis, the H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS. In H1-2022 when compared with H1-2021, the market growth rate of eye infections treatment is expected to fall by only 05 basis point share (BPS), as per FMI analysis.

The decline in the BPS values observed was attributed to the decrease in the cases of outpatient eye consultations, disruption in supply chain and distribution of ophthalmic eye drops, and the growing cases of infectious disease proliferation which was untended to during the lockdown period of the COVID-19 pandemic.

Conversely, rising pharmaceuticals production facilities in several economies such as India will splurge the growth output scenario of the overall market during the forecast period.

Key developments in the market include the development of intravitreal antibiotics. The market is highly influenced by regulatory impositions, disease epidemiology, and patient compliance, under the impact of macro and industry factors.

Analysis Of Eye Infections Treatment Industry (2015 To 2021) Vs Market Predictions (2022 To 2030)

Eye infections have seen a substantial rise in incidence over the past years and this has led to an increase in eye infections treatment demand, and this trend is expected to be prevalent over the coming years as well. The global eye disease treatment market rose at a CAGR of 3.7% from 2015 to 2021.

Increasing instances of glaucoma, cataracts, diabetic retinopathy, and age-related macular degeneration (AMD) have resulted in high demand for eye infections treatment. Rising geriatric population is one of the major factors driving the eye infections treatment industry potential.

Eye Infections Treatment Market

Increasing sedentary lifestyle trends, emergence of new allergies, rising adoption of contact lenses, rising need for pink eye treatment, and increasing rate of eye surgeries are some other factors that are driving demand for the treatment of eye infections.

Demand for eye infections treatment is anticipated to progress at a steady 3.8% CAGR from 2022 to 2030.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Factors Are Positively Influencing Eye Infections Treatment Market Potential?

“Market Driven by Rising Incidence of Multiple Vision Conditions across the World”

Instances of eye infections are expected to see a rise on a global level, and this is expected to propel demand for medicines for eye infections. Eye drops for conjunctivitis, pink eye drops, stye eye drops, and keratitis eye drops are some prominent treatment options that are expected to see high demand over the forecast period. Eye infections treatment providers are launching new products to increase their market presence and boost revenues across the world.

For instance, NovaBay Pharmaceuticals, in January 2022, announced the launch of new eye drops that are designed to treat dry eye symptoms. This is a new over-the-counter medicine for dry eyes, which is a condition that has seen an increase in incidence over the past years.

“Technical Advancements in Diagnosis & Treatment for Eye Infections to Fuel Market Potential”

Constant research & development are evident in the healthcare industry and this is common for eye disease treatment and diagnosis as well. Post-operative ocular infections have been a major cause of concern as they account for a significant amount of total eye infections in the world.

Eye infections treatment providers are investing in the research and development of new diagnostic and treatment procedures to minimize the risks of infections in ocular surgeries. Increasing technological advancements are expected to influence the eye infections treatment market over the coming years.

For instance, TearClear, an ophthalmic pharmaceutical firm, announced the initiation of phase 3 of its trial for a preservative-free ophthalmic solution. Evaluation of TC-002 in patients with glaucoma is the main focus of this trial, and this phase brings it one step closer to market launch.

How Is The Eye Infections Treatment Market Expected To Perform Across Regions?

“Emerging Economies of India and China to Provide Lucrative Opportunities”

The global eye infections treatment industry survey provides detailed analysis of the market across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).

The eye infections treatment market in North America is expected to have a bright outlook over the forecast period, and most of the growth in this region is anticipated to be driven by the easy availability of eye treatments and high adoption of eye lenses.

The market for eye infections treatment in Europe is anticipated to be majorly governed by the increasing geriatric population in the region. Rising focus on healthcare infrastructure is also expected to crucially influence market potential over the coming years.

The market for eye infections treatment in regions such as East Asia and South Asia is anticipated to see significant demand from emerging economies such as India and China. High population density in these regions and developing healthcare infrastructure provide a lucrative setting for eye infections treatment product manufacturers.

Country-Wise Analysis

Why the U.S. is a Highly Lucrative Market for Eye Infections Treatment Vendors?

“U.S. Market Driven by High Incidence of Eye Infections and Increasing Need for Eye Surgeries”

Advanced healthcare infrastructure provides a lucrative setting for eye infection treatments in the U.S. Increasing number of eye surgeries, rising usage of eye lenses, rising geriatric population, etc. are some factors that propel demand in the U.S.

Laboratoires Théa SAS, in January 2022, announced an agreement with Akorn Operating Company LLC to strengthen its presence in the U.S. eye care market. Via this agreement, Théa will be purchasing seven ophthalmic products from Akorn to fulfil the needs of eye care professionals in the U.S.

Is India a Beneficial Market for Eye Infections Treatment Providers?

“Eye Infections Treatment Companies to Benefit from Developing Healthcare Infrastructure in India”

India has seen a substantial increase in focus on eye infections treatment as instances of eye diseases in the nation has risen. Developing healthcare infrastructure provides eye infections treatment equipment suppliers an opportunity to discover the untapped market potential in India.

Increasing geriatric population, rising availability of eye infection medicines, increasing popularity of OTC eye drops, rising awareness about eye infections, etc. are major factors governing the eye infections treatment industry in India.

Category-Wise Analysis

Why is Demand for Eye Drops for Infection Treatment the Highest?

“Antibiotic Eye Drops to See Hike in Demand through 2030”

Eye drops have proven their effectiveness in the treatment of various eye diseases and eye infections and are a preferred treatment choice among patients as well. Stye eye drops, antiviral eye drops, antibiotic eye drops, pink eye drops, eye drops for conjunctivitis, and eye drops for blepharitis are some of the most used eye drops in the eye treatment industry.

OTC eye infection drops are expected to see an increase in demand. With a rise in instances of stye eye, pink eye, conjunctivitis, etc., demand for eye drops is expected to be a prominent trend over the forecast period as well.

Currently, the eye drops segment accounts for a mammoth share of 60.2% in the global eye infections treatment devices market, and is anticipated to maintain its dominance through 2030.

COVID-19 Pandemic Impact

In 2020, as the pandemic hit the world all resources were directed to fend off infections and contain coronavirus in the most effective way possible. This adversely affected the eye infections treatment marketplace and other health conditions saw a decrease in diagnostic availability.

However, as the pandemic subsides and the world returns to a new normal, we are expecting eye infections treatment to make a steady recovery. Delayed diagnostic opportunities and increased focus on healthcare are expected to be prominent trends in the post-pandemic era and influence eye infections treatment demand.

Competitive Landscape

Eye infections treatment product suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales. Approval for new medications and treatments for eye infections is also expected to be a major trend over the coming years.

In December 2021, Vuity, a new eye drop medicine was launched for presbyopia which affects millions of people across the world. It was approved by FDA in October and provides a sharper vision for 6 – 10 hours and starts showing effect in 15 minutes of application.

Eye Infections Treatment Industry Report Scope

Attribute	Details
Forecast Period	2022 to 2030
Historical Data Available for	2015 to 2021
Market Analysis	US$ Million for Value
Key Regions Covered	North America Latin America Europe East Asia South Asia & Pacific Middle East & Africa (MEA)
Key Countries Covered	United States Canada Brazil Mexico Germany UK France Spain Italy China Japan South Korea India Indonesia Malaysia Singapore Australia New Zealand Turkey South Africa and GCC Countries
Key Market Segments Covered	Drug Class Dosage Form Indication Causative Agent Distribution Channels Region
Key Companies Profiled	Allergan plc Alcon Laboratories Inc. Bausch Health Companies Inc. Pfizer Inc. Akron Pharma Inc Sanofi S.A. GlaxoSmithKline plc Intas Pharmaceuticals Ltd Johnson & Johnson Services Inc. Macleods Pharmaceuticals Ltd. Merck & Co. Inc. Mylan N.V. Teva Pharmaceutical Industries Ltd.
Pricing	Available upon Request

Key Segments Of Eye Infections Treatment Industry Survey

By Drug Class:

Antibiotics
- Sulfonamides
- Macrolides
- Erythromycin
- Chloramphenicol
- Aminoglycosides
- Fluoroquinolones
- Vancomycin
- Tetracyclines
Antivirals
- Thymidine-Based Nucleoside Analogues (Trifluridine)
- Thymidine Phosphorylase Inhibitors (Trifluridine)
- Acyclic Nucleoside Analogue of 2'Deoxyguanasine (Ganciclovir)
- Acyclic Guanine Nucleoside Analog (Acyclovir)
- Others
Antifungals
- Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
- Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
- Pyrimidines
- Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
- Others
Antihistamines
Corticosteroids
Glucocorticoids

By Dosage Form:

Eye Infections Treatment Tablets
Eye Infections Treatment Capsules
Eye Infections Treatment Ophthalmic Ointments
Eye Infections Treatment Eye Drops
Others

By Indication:

Eye Infections Treatment for Conjunctivitis
Eye Infections Treatment for Keratitis
Eye Infections Treatment for Endophthalmitis
Eye Infections Treatment for Blepharitis
Eye Infections Treatment for Stye or Sty (Hordeolum)
Eye Infections Treatment for Uveitis
Eye Infections Treatment for Cellulitis
Eye Infections Treatment for Ocular Herpes

By Causative Agent:

Virus
Bacteria
Fungus
Allergens

By Distribution Channels:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

By Region:

North America Eye Infections Treatment Market
Latin America Eye Infections Treatment Market
Europe Eye Infections Treatment Market
East Asia Eye Infections Treatment Market
South Asia & Pacific Eye Infections Treatment Market
Middle East & Africa (MEA) Eye Infections Treatment Market

Frequently Asked Questions

How is demand for eye infections treatment predicted to rise over the forecast period?

The global eye infections treatment market is projected to exhibit a CAGR of 3.8% from 2022 to 2030.

What market share is held by eye drops in 2022?

At present, eye drops account for a dominant market share of 60.2% in the global eye infections treatment industry.

Who are the prime players profiled in this eye infections treatment market survey?

Prime eye infections treatment product manufacturers are Allergan plc, Alcon Laboratories Inc., Bausch Health Companies Inc., Pfizer Inc., Akron Pharma Inc., Sanofi S.A., and GlaxoSmithKline plc.

How big is the eye infections treatment market at present?

Currently, the global eye infections treatment market is worth US$ 7.3 Bn.

What is the projected net worth for the year 2030?

The eye infections treatment market is predicted to reach an estimated valuation of US$ 9.9 Bn by 2030.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Spending Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Adoption of Drugs
4.2.2. Disease Prevalence
4.2.3. Reimbursement scenario
4.2.4. Regulatory Scenario
4.2.5. Product in Pipeline
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. Market Context
5.1. Drug Type vs Indication Analysis
5.2. Strategic Promotional Analysis, By Key Manufacturers
5.3. Key Regulations
5.4. Porter’s Five Forces Analysis
5.5. PESTLE Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 financial analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Product
6.4.2. Revenue By Dosage Form
6.4.3. Revenue By Country
6.5. 2022 Market Scenario
6.6. Quarter by Quarter Forecast
6.7. Projected recovery Quarter
6.8. Recovery Scenario - Short term, Midterm and Long Term Impact Global
7. Global Eye Infection treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030
7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015 - 2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022 - 2030
8.3.1. Antibiotics
8.3.1.1. Sulfonamides
8.3.1.2. Macrolides
8.3.1.3. Erythromycin
8.3.1.4. Chloramphenicol
8.3.1.5. Aminoglycosides
8.3.1.6. Fluoroquinolones
8.3.1.7. Vancomycin
8.3.1.8. Tetracyclines
8.3.2. Antivirals
8.3.2.1. Thymidine-Based Nucleoside Analogues (Trifluridine)
8.3.2.2. Thymidine Phosphorylase Inhibitors (Trifluridine)
8.3.2.3. Acyclic Nucleoside Analogue of 2'Deoxyguanasine (Ganciclovir)
8.3.2.4. Acyclic Guanine Nucleoside Analog (Acyclovir)
8.3.2.5. Others
8.3.3. Antifungals
8.3.3.1. Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
8.3.3.2. Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
8.3.3.3. Pyrimidines
8.3.3.4. Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
8.3.3.5. Others
8.3.4. Antihistamines
8.3.5. Corticosteroids
8.3.6. Glucocorticoids
8.4. Market Attractiveness Analysis By Drug Class
9. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Dosage Form
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Dosage Form, 2015 - 2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2022 - 2030
9.3.1. Tablet
9.3.2. Capsule
9.3.3. Ophthalmic Ointment
9.3.4. Eye Drops
9.3.5. Others
9.4. Market Attractiveness Analysis By Dosage Form
10. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Indication
10.1.Introduction / Key Findings
10.2.Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2021
10.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022 - 2030
10.3.1. Conjunctivitis
10.3.2. Keratitis
10.3.3. Endophthalmitis
10.3.4. Blepharitis
10.3.5. Stye or Sty (Hordeolum)
10.3.6. Uveitis
10.3.7. Cellulitis
10.3.8. Ocular herpes
10.4.Market Attractiveness Analysis By Indication
11. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Causative Agent
11.1.Introduction / Key Findings
11.2.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2015 - 2021
11.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Causative Agent, 2022 - 2030
11.3.1. Virus
11.3.2. Bacteria
11.3.3. Fungus
11.3.4. Allergens
11.4.Market Attractiveness Analysis By Causative Agent
12. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Distribution Channel
12.1.Introduction / Key Findings
12.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 - 2021
12.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2030
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Drug Stores
12.3.4. Online Pharmacy
12.4.Market Attractiveness Analysis By Distribution Channel
13. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Region
13.1.Introduction
13.2.Historical Market Size (US$ Mn) Analysis By Region, 2015 - 2021
13.3.Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2030
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4.Market Attractiveness Analysis By Region
14. North America Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021
14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2030
14.4.1. By Country
14.4.1.1. U.S.
14.4.1.2. Canada
14.4.2. By Drug Class
14.4.3. By Dosage Form
14.4.4. By Indications
14.4.5. By Causative Agent
14.4.6. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Drug Class
14.5.3. By Dosage Form
14.5.4. By Indications
14.5.5. By Causative Agent
14.5.6. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Latin America Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021
15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2030
15.4.1. By Country
15.4.1.1. Brazil
15.4.1.2. Mexico
15.4.1.3. Rest of Latin America
15.4.2. By Drug Class
15.4.3. By Dosage Form
15.4.4. By Indications
15.4.5. By Causative Agent
15.4.6. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Drug Class
15.5.3. By Dosage Form
15.5.4. By Indications
15.5.5. By Causative Agent
15.5.6. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. Europe Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021
16.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030
16.4.1. By Country
16.4.1.1. Germany
16.4.1.2. U.K.
16.4.1.3. France
16.4.1.4. France
16.4.1.5. Italy
16.4.1.6. Spain
16.4.1.7. Russia
16.4.1.8. Rest of Europe
16.4.2. By Drug Class
16.4.3. By Dosage Form
16.4.4. By Indications
16.4.5. By Causative Agent
16.4.6. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Drug Class
16.5.3. By Dosage Form
16.5.4. By Indications
16.5.5. By Causative Agent
16.5.6. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. South Asia Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 - 2021
17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Thailand
17.4.1.3. Indonesia
17.4.1.4. Malaysia
17.4.1.5. Rest of South Asia
17.4.2. By Drug Class
17.4.3. By Dosage Form
17.4.4. By Indications
17.4.5. By Causative Agent
17.4.6. By Distribution Channel
17.5.Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Drug Class
17.5.3. By Dosage Form
17.5.4. By Indications
17.5.5. By Causative Agent
17.5.6. By Distribution Channel
17.6.Market Trends
17.7.Key Market Participants - Intensity Mapping
17.8.Drivers and Restraints - Impact Analysis
18. East Asia Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 - 2021
18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030
18.4.1. By Country
18.4.1.1. China
18.4.1.2. Japan
18.4.1.3. South Korea
18.4.2. By Drug Class
18.4.3. By Dosage Form
18.4.4. By Indications
18.4.5. By Causative Agent
18.4.6. By Distribution Channel
18.5.Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Drug Class
18.5.3. By Dosage Form
18.5.4. By Indications
18.5.5. By Causative Agent
18.5.6. By Distribution Channel
18.6 .Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Oceania Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
19.1.Introduction
19.2.Pricing Analysis
19.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021
19.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030
19.4.1. By Country
19.4.1.1. Australia
19.4.1.2. New Zealand
19.4.2. By Drug Class
19.4.3. By Dosage Form
19.4.4. By Indications
19.4.5. By Causative Agent
19.4.6. By Distribution Channel
19.5.Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Drug Class
19.5.3. By Dosage Form
19.5.4. By Indications
19.5.5. By Causative Agent
19.5.6. By Distribution Channel
19.6.Market Trends
19.7.Key Market Participants - Intensity Mapping
19.8.Drivers and Restraints - Impact Analysis
20. Middle East and Africa Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
20.1.Introduction
20.2.Pricing Analysis
20.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021
20.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030
20.4.1. By Country
20.4.1.1. GCC Countries
20.4.1.2. Turkey
20.4.1.3. Northern Africa
20.4.1.4. South Africa
20.4.1.5. Rest of Middle East and Africa
20.4.2. By Drug Class
20.4.3. By Dosage Form
20.4.4. By Indications
20.4.5. By Causative Agent
20.4.6. By Distribution Channel
20.5.Market Attractiveness Analysis
20.5.1. By Country
20.5.2. By Drug Class
20.5.3. By Dosage Form
20.5.4. By Indications
20.5.5. By Causative Agent
20.5.6. By Distribution Channel
20.6.Market Trends
20.7.Key Market Participants - Intensity Mapping
20.8.Drivers and Restraints - Impact Analysis
21. Emerging Countries Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030
21.1.Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2.China Eye Infection treatment Market Analysis
21.2.1. Introduction
21.2.2. Pricing Analysis
21.2.3. PEST Analysis
21.2.4. Market Value Proportion Analysis by Market Taxonomy
21.2.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.2.5.1. By Drug Class
21.2.5.2. By Dosage Form
21.2.5.3. By Indications
21.2.5.4. By Causative Agent
21.2.5.5. By Distribution Channel
21.2.6. China Eye Infection treatment Market - Competition Landscape
21.2.7. China - Trade Analysis
21.3.India Eye Infection treatment Market Analysis
21.3.1. Introduction
21.3.2. Pricing Analysis
21.3.3. PEST Analysis
21.3.4. Market Value Proportion Analysis by Market Taxonomy
21.3.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.3.5.1. By Drug Class
21.3.5.2. By Dosage Form
21.3.5.3. By Indications
21.3.5.4. By Causative Agent
21.3.5.5. By Distribution Channel
21.3.6. India Eye Infection treatment Market - Competition Landscape
21.4.Brazil Eye Infection treatment Market Analysis
21.4.1. Introduction
21.4.2. Pricing Analysis
21.4.3. PEST Analysis
21.4.4. Market Value Proportion Analysis by Market Taxonomy
21.4.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.4.5.1. By Drug Class
21.4.5.2. By Dosage Form
21.4.5.3. By Indications
21.4.5.4. By Causative Agent
21.4.5.5. By Distribution Channel
21.4.6. Brazil Eye Infection treatment Market - Competition Landscape
22. Market Structure Analysis
22.1.Market Analysis by Tier of Companies (Eye Infection treatment)
22.2.Market Concentration
22.3.Market Share Analysis of Top Players
22.4.Market Presence Analysis
22.4.1. By Regional footprint of Players
22.4.2. Product foot print by Players
22.4.3. Channel Foot Print by Players
23. Competition Analysis
23.1.Competition Dashboard
23.2.Pricing Analysis by Competition
23.3.Competition Benchmarking
23.4.Competition Deep Dive
23.4.1. Allergan plc
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Profitability by Market Segments (Product/Channel/Region)
23.4.1.4. Sales Footprint
23.4.1.5. Strategy Overview
23.4.1.5.1. Marketing Strategy
23.4.1.5.2. Product Strategy
23.4.1.5.3. Channel Strategy
23.4.2. Alcon Laboratories, Inc.
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Profitability by Market Segments (Product/Channel/Region)
23.4.2.4. Sales Footprint
23.4.2.5. Strategy Overview
23.4.2.5.1. Marketing Strategy
23.4.2.5.2. Product Strategy
23.4.2.5.3. Channel Strategy
23.4.3. Bausch Health Companies Inc.
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Profitability by Market Segments (Product/Channel/Region)
23.4.3.4. Sales Footprint
23.4.3.5. Strategy Overview
23.4.3.5.1. Marketing Strategy
23.4.3.5.2. Product Strategy
23.4.3.5.3. Channel Strategy
23.4.4. Pfizer Inc.
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Profitability by Market Segments (Product/Channel/Region)
23.4.4.4. Sales Footprint
23.4.4.5. Strategy Overview
23.4.4.5.1. Marketing Strategy
23.4.4.5.2. Product Strategy
23.4.4.5.3. Channel Strategy
23.4.5. Akron Pharma Inc.
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Profitability by Market Segments (Product/Channel/Region)
23.4.5.4. Sales Footprint
23.4.5.5. Strategy Overview
23.4.5.5.1. Marketing Strategy
23.4.5.5.2. Product Strategy
23.4.5.5.3. Channel Strategy
23.4.6. Sanofi S.A.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Profitability by Market Segments (Product/Channel/Region)
23.4.6.4. Sales Footprint
23.4.6.5. Strategy Overview
23.4.6.5.1. Marketing Strategy
23.4.6.5.2. Product Strategy
23.4.6.5.3. Channel Strategy
23.4.7. GlaxoSmithKline plc
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Profitability by Market Segments (Product/Channel/Region)
23.4.7.4. Sales Footprint
23.4.7.5. Strategy Overview
23.4.7.5.1. Marketing Strategy
23.4.7.5.2. Product Strategy
23.4.7.5.3. Channel Strategy
23.4.8. Intas Pharmaceuticals Ltd
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Profitability by Market Segments (Product/Channel/Region)
23.4.8.4. Sales Footprint
23.4.8.5. Strategy Overview
23.4.8.5.1. Marketing Strategy
23.4.8.5.2. Product Strategy
23.4.8.5.3. Channel Strategy
23.4.9. Johnson & Johnson Services, Inc.
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Profitability by Market Segments (Product/Channel/Region)
23.4.9.4. Sales Footprint
23.4.9.5. Strategy Overview
23.4.9.5.1. Marketing Strategy
23.4.9.5.2. Product Strategy
23.4.9.5.3. Channel Strategy
23.4.10. Macleods Pharmaceuticals Ltd.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Profitability by Market Segments (Product/Channel/Region)
23.4.10.4. Sales Footprint
23.4.10.5. Strategy Overview
23.4.10.5.1. Marketing Strategy
23.4.10.5.2. Product Strategy
23.4.10.5.3. Channel Strategy
23.4.11. Merck & Co., Inc.
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Profitability by Market Segments (Product/Channel/Region)
23.4.11.4. Sales Footprint
23.4.11.5. Strategy Overview
23.4.11.5.1. Marketing Strategy
23.4.11.5.2. Product Strategy
23.4.11.5.3. Channel Strategy
23.4.12. Mylan N.V.
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Profitability by Market Segments (Product/Channel/Region)
23.4.12.4. Sales Footprint
23.4.12.5. Strategy Overview
23.4.12.5.1. Marketing Strategy
23.4.12.5.2. Product Strategy
23.4.12.5.3. Channel Strategy
23.4.13. Teva Pharmaceutical Industries Ltd.
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Profitability by Market Segments (Product/Channel/Region)
23.4.13.4. Sales Footprint
23.4.13.5. Strategy Overview
23.4.13.5.1. Marketing Strategy
23.4.13.5.2. Product Strategy
23.4.13.5.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology